Series Listing



Monotherapy, Combination Therapy, Triple Therapy: What Is Ideal for Your Type 2 Patients?

Despite the availability of more treatment options than ever before, the majority of patients with type 2 diabetes mellitus (T2DM) fail to achieve recommended glycemic goals and are thus at increased risk of microvascular complications and faster disease progression.

Each course offers:
Webcast: 1.50 / AMA PRA Category 1 CreditTM

Novel Treatment of Inflammatory Bowel Disease Informed by Science and Patient Choice

Inflammatory bowel disease (IBD), which consists of Crohn's disease and ulcerative colitis, is a chronic inflammatory disease of the gut that develops because of an excessive immune response to the normal gut flora in a genetically susceptible host. Current therapies for IBD have not, as yet, been able to prevent the need for surgical intervention in more than 50% of patients with IBD. Education for clinicians who manage patients with moderate-to-severe IBD about the immunopathophysiology of IBD and the latest available options to individualize IBD treatment can reduce the use of corticosteroids and need for hospitalizations or surgery, resulting in improved quality of life for these patients.

Each activity worth:
0.50 / AMA PRA Category 1 CreditTM
0.50 contact hours for Pharmacists (0.05 CEUs)

Exploring Other Pathways to CV Risk Reduction

Thanks in part to the widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) levels, rates of cardiac events and mortality have decreased markedly. Still, data show that cardiovascular disease (CVD) accounted for 1 of every 3 deaths in the United States in recent years, leaving much room for improvement. Because achieving LDL-C targets does not completely eliminate CVD risk, attention has turned to other management approaches, including agents that address high-density lipoprotein cholesterol (HDL-C) levels, and other means of reducing residual risk. Assessing these new and emerging treatment strategies is an important step in developing an optimal approach to reducing CVD risk.

Each activity is worth:
0.50 / AMA PRA Category 1 Credit(s)TM

Strategies to Improve the Assessment and Treatment of Psoriasis

This 5-module series will provide a complete and detailed overview of psoriasis, examining pathophysiology, diagnosis and assessment of the disease, treatment safety and adherence, early intervention and referral, and comorbidities and monitoring.

Each activity offers:
0.50 / AMA PRA Category 1 CreditsTM
0.50 / CE for Nurses

Emerging Technologies in Breast Cancer Imaging: Is CESM the Answer?

Accurate mammograms are limited in dense breasts where surrounding fibroglandular tissue decreases the view of lesions. Even when tumors are detected, the full extent of the disease may not be clearly visible. New advances in breast imaging technologies include the use of contrast-enhanced spectral mammography (CESM), a safe and effective screening tool for the potential detection and diagnosis of cancerous lesions. This series of 5 independent 1 hour accredited activities will discuss the use of this screening tool in clinical practice as it compares to other imaging technologies.


Each activity offers:
1.00 AMA PRA Category 1 Credit(s)TM

Stroke Management Series

With the emergence of positive clinical trial data and subsequent updates in Acute Ischemic Stroke Guidelines, endovascular therapy, as per The American Heart Association, provides clinical benefits in selected patients with acute ischemic stroke and systems of care should be organized to facilitate the delivery of endovascular therapy. The following two webcasts will provide treating clinicians guidance on patient selection and how to best achieve optimal clinical outcomes.

Each activity offers:
1.25 AMA PRA Category 1 CreditsTM
1.40 CE for Nurses (1.40 pharmacology credits)
1.00-1.50 Category A CE Credits for Radiologic Technologists

SGLT2 Inhibitors in Type 2 Diabetes: Incorporating New Approaches Into Practice Through an Interdisciplinary Exploration

The sodium-glucose cotransporter 2 (SGLT2) inhibitors, the newest drug class in the type 2 diabetes mellitus (T2DM) treatment arsenal, target renal glucose reabsorption as a means of reducing hyperglycemia. Three agents in this class, canagliflozin, dapagliflozin, and empagliflozin, are approved to treat T2DM in the United States, as are fixed-dose combinations of some SGLT2 inhibitors with metformin or a DPP-4 inhibitor. To leverage the potential benefits of these agents and improve patient outcomes, clinicians need to be aware of the most recent data on the SGLT2 inhibitors and when and how to incorporate them into T2DM management plans.

Each activity offers:
Roundtable Discussion: 1.00 AMA PRA Category 1 CreditTM
Clinical Consult Case 1: 0.50 AMA PRA Category 1 CreditTM
Clinical Consult Case 2: 0.50 AMA PRA Category 1 CreditTM

Improving Treatment and Adherence in Schizophrenia and Schizoaffective Disorder

This 3-part CME podcast series will provide an in-depth look at the most recent evidence on appropriate treatment paradigms for schizophrenia and schizoaffective disorder; strategies for improving adherence to antipsychotic therapy; the risks and benefits of long-acting injectable antipsychotics and evidence-based guidelines for use of these formulations; and implementation of individualized treatment strategies.


Each podcast is certified for up to 0.50 AMA PRA Category 1 Credit(s)TM.

Adopting a Patient-Centered Approach in the Management of COPD to Improve the Continuum of Care

Treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) remains the major factor in increasing healthcare costs associated with COPD. Patients who survive severe exacerbations of COPD are at higher risk of hospital readmission and death. The challenges of assessment of COPD and exacerbation severity are compounded by nonadherence or inadequate medical management.


Each activity offers:
Roundtable Discussion: 1.00 AMA PRA Category 1 CreditTM
Specialty House Calls Case 1: 0.50 AMA PRA Category 1 CreditTM
Specialty House Calls Case 2: 0.50 AMA PRA Category 1 CreditTM
Q&A Session: 0.50 AMA PRA Category 1 CreditTM

Dyslipidemia: When Statins Aren't Enough

The curriculum offers two structured, multi-component interactive enduring activities that are focused on new and emerging treatment strategies that may offer additional therapeutic options as a complement to statin therapy or as a standalone therapy for the patient at higher CVD risk.

Each activity worth:
1.00 / AMA PRA Category 1 CreditTM
1.00 / CE for Nurses
1.00 / CE for Nurse Practitioners (0.75 pharmacology credits) 

Biosimilars Series

Biosimilar medications are "highly similar" to an already FDA-approved biological product. One biosimilar is approved in the US, with more sure to follow in the near future, including a biosimilar insulin that is likely to have a significant impact on diabetes management.

Although they will be responsible for ensuring safe and effective use of biosimilars, many clinicians are not familiar with the distinctions between biosimilars and generic drugs, including the different approval processes and regulatory issues surrounding these agents.

To clarify those questions and provide background and guidance two CME programs are being offered.

Credits:
Part I offers 1.00 AMA PRA Category 1 Credit(s)TM
Part II offers 0.50 AMA PRA Category 1 Credit(s)TM

Moving Beyond Laxatives in OIC: New Targets, New Strategies, New Outcomes

The majority of patients treated with opioid therapy for cancer and non-cancer pain experience opioid-induced constipation (OIC). This condition is not trivial as it affects the patient's quality of life and can lead them to reduce, discontinue, or change effective analgesic therapy. The spectrum of laxative classes currently available do not provide effective results in this setting, primarily because they do not address the mechanisms by which opioids cause OIC. Research advances have improved the understanding of those underlying mechanisms and have resulted in the identification of new pharmacologic agents that target the μ-opioid receptor interaction while maintaining the analgesic benefit of the opioid and minimizing the risk of withdrawal.

Module 1 worth:
1.00 / AMA PRA Category 1 CreditTM
1.00 contact hours for Pharmacists (0.10 CEUs)

Module 2 worth:
0.50 / AMA PRA Category 1 CreditTM

Module 3 worth:
0.75 / AMA PRA Category 1 CreditTM

BED Clinical Consultations

This 4-part enduring webinar series is designed for general medicine and family physicians, dietitians and other healthcare providers who currently manage patients with BED or who are seeking to increase their knowledge about eating disorders.

Each activity worth:
1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / CPEU Credit for Dietitians

Incorporating Advancements in Monoclonal Antibody Therapeutics into Patient Management Strategies for Dyslipidemia

This CME/CE program addresses scientific advancements in monoclonal antibody therapy and the management of patients with dyslipidemia. The unique educational format of this initiative includes a learner driven, interactive, on-demand, webcast structured as three 20-minute modules that will each be delivered using the unique ArcheMedX Platform. This program aims to arm health care providers with information on disease management, diagnosis, and emergent clinical trial data in order to improve the care administered to patients with dyslipidemia. The interactive set-up of this CME/CE program will provide an optimal learner experience, resulting in greater quality care for patients in practice.


Each module offers:
0.50 / AMA PRA Category 1 CreditTM  for Physicians, per module
0.50 contact hours for Pharmacists (0.05 CEUs), per module
0.40 and 0.30 contact hours for Nurses (module 1 and 2, 0.40 CE's; module 3, 0.30 CE's)

New Paradigm of Molecular Targeted Therapy for Metastatic Colorectal Cancer

This series of 3 activities is designed to meet the educational needs of medical oncologists and other health care professionals who diagnose, treat, and manage patients with colorectal cancer.

Modules 1 and 2 each offer 0.50 AMA PRA Category 1 Credit(s)TM
Module 3 offers 0.75 AMA PRA Category 1 Credit(s)TM

Multimodal Interventions for Obesity Series

This series of 2 integrated articles will present the latest data on issues related to the assessment of overweight and obesity; appropriate counseling and integration of lifestyle interventions; and a critical appraisal of new pharmacologic therapies for weight management.


Each activity worth:
0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CE for Nurses

Targeting the Kidney in Diabetes

This series of 3 activities reviews the rationale behind and clinical applications of the most recently available class of antidiabetes medications—sodium-glucose transporter 2 inhibitors.


Each activity worth:
0.50 / AMA PRA Category 1 Credit(s)TM

The Link Between Early Childhood Nutrition and Long-Term Health

This series of CME/CE articles present the latest evidence-based data on best nutritional practices for young patients.


Each activity worth:
0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CE for Nurses
0.50 / CPEU

Recognizing and Treating Shift Work Disorder: Strategies to Optimize Sleep and Alertness

Despite the prevalence of shift work in the United States and the fact that shift work sleep/wake disorder (SWSWD) poses serious risks to the individual's functioning, health, safety, and quality of life, the disorder remains largely under-recognized, underdiagnosed, and undertreated.

This 3-module series is designed for physicians, nurse practitioners, and physician assistants working in primary care or family practice settings.

Each activity worth:
0.50 / AMA PRA Category 1 Credit(s)TM

The ABC's of Binge Eating Disorder: A Primer for Primary Care Practice

Binge eating disorder (BED) is the most prevalent eating disorder in the US—affecting more people than bulimia and anorexia combined. This 5-module series, designed for primary care/family medicine clinicians, explores the many aspects of this disorder.

Each activity worth:
0.25 / AMA PRA Category 1 Credit(s)TM
0.25 / AAFP Prescribed Credit

Strategies to Improve Adherence and Clinical Management of OAB

This 3-module series is designed to improve clinician knowledge and performance related to discussions with patients about optimal treatment plans and medication adherence in the management of overactive bladder (OAB).

Activities no longer available for credit

Joslin Diabetes Forum

Primary care clinicians oversee the management of most patients who have diabetes or are at risk to develop it. The challenge is how to prevent, diagnose, and optimally treat this complex medical condition in a timely and cost-efficient manner in a primary care practice.

Activities no longer available for credit

Improving Outcomes in Type 2 Diabetes Mellitus

This series will consider the pathobiology and pharmacotherapy of T2DM, means of overcoming barriers to insulin therapy in T2DM, nonpharmacologic approaches to treating T2DM and reducing cardiometabolic risk, and management of dyslipidemia.

Activities no longer available for credit

Cease Smoking Today Series

Cease Smoking Today (CS2day) is a collaborative partnership designed to reduce the number of persons who smoke and decrease morbidity and mortality from tobacco-related illness through integrated educational interventions.

Activities no longer available for credit

Taking the Pulse of Neonatal Screening for Critical Congenital Heart Disease

This 3-part series, directed to nurse practitioners and physician assistants, is designed to take the learner from a comprehensive understanding of critical congenital heart disease, the imperatives of appropriate neonatal oximetry screening and implementation of standardized protocols nationwide, to discussion of the continuum of care from assessment and diagnosis to management decisions and follow-up post-discharge.

Activities no longer available for credit

Non-Small Cell Lung Cancer iNewsletter Series

Approximately 87% of lung cancer cases in the U.S. are classified as non-small cell lung cancer (NSCLC), and most cases are diagnosed at an advanced stage with poor overall survival. Major steps in the molecular era of lung cancer treatment are being made as clinicians not only rely on histologic classification of lung cancer to guide therapy, but also define lung cancer tumor types based on specific molecular profiles. The use of molecularly targeted therapies represents a significant advance in the treatment of NSCLC.

The gap between optimal management of advanced NSCLC and current clinical practice is widening as many oncologists remain unaware of how best to apply new and emerging clinical evidence into their clinical practice. Oncologists and other cancer professionals have an opportunity to prolong life and improve the quality of life in selected patients with advanced NSCLC by more thoroughly defining molecular subsets of advanced NSCLC and more fully integrating the use of targeted therapies into treatment regimens.

Activities no longer available for credit

Joslin Diabetes Center Professional Education

The AMA has called PI (Performance Improvement) the “core of the new CME”. PI is regarded as an effective way to identify deficiencies in your individual practice and then take steps to close those gaps. Joslin has four PI pathways in the area of diabetes to help you improve the care of your patients. These activities are approved through the American Board of Internal Medicine’s (ABIM) Approved Quality Improvement (AQI) Pathway and are eligible for 20 points towards the Self-Evaluation of Practice Performance requirement of Maintenance of Certification (MOC).

Activities no longer available for credit

Johns Hopkins University School of Medicine Cardiovascular & Cardiometabolic Disease Webcasts

Cardiovascular & Metabolic Disorders are the leading cause of death in the US, primarily due to the effects of heart disease and stroke. Nearly 2,300 Americans die of CVD every day, including a substantial number of individuals who are less than 65 years of age. This webcast series is designed to help clinicians improve their ability to diagnose, manage, and treat cardiovascular and metabolic disorders. Each activity features a moderated case discussion with faculty from the Johns Hopkins Division of Cardiology, a world-renowned center for every aspect of cardiovascular care and research.

Activities no longer available for credit

is free, fast, and customized just for you!

Already a member?

Sign In Now »

is free, fast, and customized just for you!

Already a member?

Sign In Now »